Skip to main content

Table 2 Multivariate analyses of outcomes

From: Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

OutcomeHazard ratio (95% CI)P value
ANC recovery
 Cohort ATG-PTCy vs ATG0.29 (0.21–0.41)< 0.001
Other significant factors
 Mononuclear cell count1.09 (1.04–1.14)< 0.001
 CD34+ cell count1.08 (1.01–1.15)0.012
Platelet recovery
 Cohort ATG-PTCy vs ATG0.30 (0.21–0.42)< 0.001
Other significant factors
 Mononuclear cell count1.06 (1.01–1.11)0.008
Acute GvHD ≥ grade 2
 Cohort ATG-PTCy vs ATG0.58 (0.35–0.96)0.036
Acute GvHD ≥ grade 3
 Cohort ATG-PTCy vs ATG0.28 (0.11–0.69)0.006
Total chronic GvHD
 Cohort ATG-PTCy vs ATG0.60 (0.38–0.99)0.047
Non-relapse mortality
 Cohort ATG-PTCy vs ATG0.26 (0.08–0.75)0.014
Disease risk index
 Low/int vs high0.28 (0.12–0.68)0.005
 Cohort ATG-PTCy vs ATG0.65 (0.28–1.50)0.31
Disease-free survival
 Cohort ATG-PTCy vs ATG0.44 (0.22–0.86)0.016
Disease risk index
 Low/int vs high0.51 (0.27–0.99)0.048
Overall survival
 Cohort ATG-PTCy vs ATG0.47 (0.22–1.01)0.055
Disease risk index
 Low/int vs high0.48 (0.23–0.99)0.048
GVHD and relapse-free survival
 Cohort ATG-PTCy vs ATG0.59 (0.38–0.92)0.021